These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
519 related articles for article (PubMed ID: 19097992)
1. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Yang TM; Barbone D; Fennell DA; Broaddus VC Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992 [TBL] [Abstract][Full Text] [Related]
2. Rounding up apoptosis resistance targets in lung cancer. Powell CA Am J Respir Cell Mol Biol; 2009 Jul; 41(1):7-8. PubMed ID: 19525385 [No Abstract] [Full Text] [Related]
3. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. Song JH; Kandasamy K; Kraft AS J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488 [TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. Barbone D; Yang TM; Morgan JR; Gaudino G; Broaddus VC J Biol Chem; 2008 May; 283(19):13021-30. PubMed ID: 18339627 [TBL] [Abstract][Full Text] [Related]
5. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365 [TBL] [Abstract][Full Text] [Related]
6. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246 [TBL] [Abstract][Full Text] [Related]
7. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL. Hari Y; Harashima N; Tajima Y; Harada M Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422 [TBL] [Abstract][Full Text] [Related]
8. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337 [TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017 [TBL] [Abstract][Full Text] [Related]
10. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385 [TBL] [Abstract][Full Text] [Related]
11. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021 [TBL] [Abstract][Full Text] [Related]
12. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Wang X; Chen W; Zeng W; Bai L; Tesfaigzi Y; Belinsky SA; Lin Y Mol Cancer Ther; 2008 May; 7(5):1156-63. PubMed ID: 18483303 [TBL] [Abstract][Full Text] [Related]
13. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153 [TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429 [TBL] [Abstract][Full Text] [Related]
15. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218 [TBL] [Abstract][Full Text] [Related]
16. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Rooswinkel RW; van de Kooij B; Verheij M; Borst J Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003 [TBL] [Abstract][Full Text] [Related]
17. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. Barbone D; Cheung P; Battula S; Busacca S; Gray SG; Longley DB; Bueno R; Sugarbaker DJ; Fennell DA; Broaddus VC PLoS One; 2012; 7(12):e52753. PubMed ID: 23300762 [TBL] [Abstract][Full Text] [Related]
18. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332 [TBL] [Abstract][Full Text] [Related]
19. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Barbone D; Ryan JA; Kolhatkar N; Chacko AD; Jablons DM; Sugarbaker DJ; Bueno R; Letai AG; Coussens LM; Fennell DA; Broaddus VC Cell Death Dis; 2011 Jun; 2(6):e174. PubMed ID: 21697949 [TBL] [Abstract][Full Text] [Related]
20. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737. Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]